J1O-MC-JZHD: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512102-25-00

Acronym

JIO-MC-JZHD

Enrollment

Registered

2024-08-13

Start date

2020-07-29

Completion date

Unknown

Last updated

2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Brief summary

dose-limiting toxicity, safety, including, but not limited to TEAEs (treatment-emergent adverse events), SAEs (serious adverse events), deaths, and clinical laboratory, abnormalities per CTCAE (Common Terminology Criteria for Adverse Events) (Version 5.0), overall response rate, overall Survival

Interventions

None listed

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
dose-limiting toxicity, safety, including, but not limited to TEAEs (treatment-emergent adverse events), SAEs (serious adverse events), deaths, and clinical laboratory, abnormalities per CTCAE (Common Terminology Criteria for Adverse Events) (Version 5.0), overall response rate, overall Survival	—

Countries

Spain

Outcome results